These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 26936398)
61. Epigenetic silencing and activation of transcription: influence on the radiation sensitivity of glioma cell lines. Sak A; Kübler D; Bannik K; Groneberg M; Strunz S; Kriehuber R; Stuschke M Int J Radiat Biol; 2017 May; 93(5):494-506. PubMed ID: 28044469 [TBL] [Abstract][Full Text] [Related]
62. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells. Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008 [TBL] [Abstract][Full Text] [Related]
63. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. Fisher ML; Adhikary G; Grun D; Kaetzel DM; Eckert RL Mol Carcinog; 2016 Dec; 55(12):2024-2036. PubMed ID: 26693692 [TBL] [Abstract][Full Text] [Related]
64. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841 [TBL] [Abstract][Full Text] [Related]
65. Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma. Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I Anticancer Agents Med Chem; 2017; 17(2):190-205. PubMed ID: 27109020 [TBL] [Abstract][Full Text] [Related]
66. The Polycomb group protein EZH2 directly controls DNA methylation. Viré E; Brenner C; Deplus R; Blanchon L; Fraga M; Didelot C; Morey L; Van Eynde A; Bernard D; Vanderwinden JM; Bollen M; Esteller M; Di Croce L; de Launoit Y; Fuks F Nature; 2006 Feb; 439(7078):871-4. PubMed ID: 16357870 [TBL] [Abstract][Full Text] [Related]
67. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. Tsang DP; Cheng AS J Gastroenterol Hepatol; 2011 Jan; 26(1):19-27. PubMed ID: 21175789 [TBL] [Abstract][Full Text] [Related]
68. EZH2 in normal hematopoiesis and hematological malignancies. Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210 [TBL] [Abstract][Full Text] [Related]
69. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396 [TBL] [Abstract][Full Text] [Related]
70. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. Anichini A; Molla A; Nicolini G; Perotti VE; Sgambelluri F; Covre A; Fazio C; Lofiego MF; Di Giacomo AM; Coral S; Manca A; Sini MC; Pisano M; Noviello T; Caruso F; Brich S; Pruneri G; Maurichi A; Santinami M; Ceccarelli M; Palmieri G; Maio M; Mortarini R; J Exp Clin Cancer Res; 2022 Nov; 41(1):325. PubMed ID: 36397155 [TBL] [Abstract][Full Text] [Related]
71. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Wen Y; Cai J; Hou Y; Huang Z; Wang Z Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635 [TBL] [Abstract][Full Text] [Related]
72. Inhibition of Ezh2 In Vitro and the Decline of Hong F; Zhao M; Zhang L; Feng L Stem Cells Dev; 2019 May; 28(10):649-658. PubMed ID: 30887911 [TBL] [Abstract][Full Text] [Related]
73. AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis. White JR; Thompson DT; Koch KE; Kiriazov BS; Beck AC; van der Heide DM; Grimm BG; Kulak MV; Weigel RJ Cancer Res; 2021 Sep; 81(17):4455-4470. PubMed ID: 34210752 [TBL] [Abstract][Full Text] [Related]
74. Epigenetic modification in gliomas: role of the histone methyltransferase EZH2. Bian EB; Li J; He XJ; Zong G; Jiang T; Li J; Zhao B Expert Opin Ther Targets; 2014 Oct; 18(10):1197-206. PubMed ID: 25046371 [TBL] [Abstract][Full Text] [Related]
75. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis. Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967 [TBL] [Abstract][Full Text] [Related]
76. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. Guan J; Gupta R; Filipp FV Sci Rep; 2015 Jan; 5():7857. PubMed ID: 25600636 [TBL] [Abstract][Full Text] [Related]
77. Plasma cell differentiation is controlled by multiple cell division-coupled epigenetic programs. Scharer CD; Barwick BG; Guo M; Bally APR; Boss JM Nat Commun; 2018 Apr; 9(1):1698. PubMed ID: 29703886 [TBL] [Abstract][Full Text] [Related]
78. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma. Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240 [TBL] [Abstract][Full Text] [Related]
79. DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Lauss M; Aine M; Sjödahl G; Veerla S; Patschan O; Gudjonsson S; Chebil G; Lövgren K; Fernö M; Månsson W; Liedberg F; Ringnér M; Lindgren D; Höglund M Epigenetics; 2012 Aug; 7(8):858-67. PubMed ID: 22705924 [TBL] [Abstract][Full Text] [Related]